Novozymes' bioenergy unit exceeds consensus amid wide H1 setback

Novozymes' bioenergy unit was the company's only division to perform better than expected. Altogether, the group had to swallow a negative organic growth of 3 percent for the first half of 2019.

Photo: Keld Navntoft / Ritzau Scanpix

Log in to read our articles

Welcome to EnergyWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles

Latest News


See all

See all